
Fully human antibodies, developed using human genes, are advancing antibody-based therapeutics. These antibodies reduce immunogenicity, improving patient safety and tolerance. Traditional methods, like humanized mice, require genetic modifications to produce human antibodies, often increasing complexity and cost.
The collaboration between Biointron and Cyagen addresses these challenges with a next-generation platform. By combining Biointron's AbDrop™ technology and Cyagen's HUGO-Ab™ mice, researchers can discover fully human antibodies faster and at a lower cost. This platform accelerates timelines, reduces expenses, and delivers safer and more effective antibody candidates.
Key Advantages of the Biointron and Cyagen Platform
1. Faster Results
The platform significantly reduces timelines by eliminating the humanization process. Fully human antibodies can be identified within three months. This rapid turnaround is critical for biopharmaceutical companies aiming to bring therapies to market quickly.
2. Enhanced Accuracy and Diversity
Access to a diverse pool of high-affinity and highly specific antibodies ensures optimal targeting for therapeutic applications. The platform's precision reduces the risk of off-target effects, improving drug efficacy and safety.
3. Cost-Effectiveness
By streamlining the discovery process and leveraging cutting-edge technologies, the platform minimizes development costs.
4. Clear Intellectual Property (IP) and Royalty-Free Structure
A straightforward IP framework ensures smooth licensing and development processes, removing potential legal hurdles associated with patent disputes.
Our High-throughput Fully Human Antibody Discovery Platform integrates Cyagen’s HUGO-Ab™ mice with Biointron’s AbDrop™ microdroplet-based single B cell screening. This powerful combination accelerates the discovery and development of fully human antibodies, reducing the time from target identification to therapeutic candidate to just three months. Learn more about the service here.
Polyclonal antibodies (pAbs) represent one of the earliest forms of antibody the……
A new generation of biotech companies is rapidly advancing the antibody landscap……
March 2026 saw a surge in antibody dealmaking, focusing on T-cell engagers and a……
Clinical drug development remains associated with a high failure rate, primarily……
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
Biointron uses cookies and similar technologies to ensure proper website functionality, understand how visitors use our website, and improve our content and services. Necessary cookies are enabled by default.
By clicking “Accept All”, you agree to the use of all cookies, including analytics and optional cookies that help us understand website usage and improve user experience. By clicking “Reject Non-Essential”, only necessary cookies will be used.
You may manage or change your cookie preferences at any time by clicking “Cookie Settings” at the bottom of the website.
For more information about how we use cookies and process personal data, please review our Privacy Policy.



